Bronchospasm is contraction of the smooth muscle surrounding the bronchi and bronchioles, the airways that conduct air within the lungs. This contraction narrows the airways and increases resistance to airflow, particularly during expiration. It is a physiological event rather than a single disease and commonly occurs in asthma, although it can accompany other respiratory conditions, allergic reactions, and airway irritation. Its effects range from mild, transient airflow limitation to life-threatening respiratory obstruction.
Mechanism
Airway diameter depends partly on the balance between smooth-muscle contraction and relaxation. Contraction can be triggered through neural pathways, including signals carried by the vagus nerve, or by chemical mediators released during allergic and inflammatory reactions.
Narrowing increases the effort needed to move air through the lungs. During expiration, the airways naturally become smaller as pressure within the chest rises, making expiratory airflow especially vulnerable to obstruction. Severe narrowing can prevent complete exhalation before the next breath, producing air trapping and lung hyperinflation.
Bronchospasm often occurs alongside inflammation, swelling of the airway lining, and increased mucus production. These processes further reduce airway diameter but are distinct from smooth-muscle contraction. Consequently, not all airway obstruction is bronchospasm, and not all components of an obstructive episode respond equally to medicines that relax airway muscle.
Bronchoconstriction is a broader term for narrowing caused by airway smooth-muscle contraction and is often used interchangeably with bronchospasm. Neither term, by itself, establishes the underlying diagnosis.
Associated conditions and triggers
Bronchospasm is a major component of asthma, in which the airways may respond excessively to stimuli that have little effect on unaffected individuals. Common contexts include:
- Allergic exposure: In susceptible people, exposure to allergens can trigger airway narrowing. Bronchospasm may also occur during anaphylaxis, a systemic allergic reaction.
- Respiratory infections: Viral infections can provoke episodes, particularly in people with underlying airway hyperresponsiveness.
- Inhaled irritants: Tobacco smoke, air pollution, chemical fumes, and occupational exposures can trigger bronchospasm.
- Exercise: Exercise-induced bronchoconstriction is associated with airway drying and cooling during increased ventilation. It can occur with or without otherwise established asthma.
- Medicines: Nonselective beta blockers can provoke bronchospasm in susceptible individuals. Aspirin and other nonsteroidal anti-inflammatory drugs can trigger respiratory reactions in people with aspirin-exacerbated respiratory disease.
- Airway procedures: Airway instrumentation during anesthesia can provoke bronchospasm, particularly in people with reactive airways.
A reversible bronchospastic component can also occur in chronic obstructive pulmonary disease, although its persistent airflow limitation involves additional structural and inflammatory changes.
Clinical features
Typical manifestations include wheezing, shortness of breath, chest tightness, and cough. Examination may reveal prolonged expiration, reduced air entry, rapid breathing, and increased use of accessory breathing muscles.
Wheezing results from airflow through narrowed airways, but its loudness does not reliably indicate the severity of obstruction. In very severe bronchospasm, airflow may become too limited to produce an audible wheeze, resulting in a “silent chest.”
Severe episodes can impair oxygen uptake and, as respiratory muscles fatigue, carbon dioxide elimination. Exhaustion, altered consciousness, and respiratory failure can occur in advanced obstruction.
Assessment and differential diagnosis
Assessment draws on the circumstances of onset, medical history, physical examination, and measurements of airflow and oxygenation. Spirometry can demonstrate expiratory airflow obstruction. Improvement after a bronchodilator supports reversible airflow limitation, although this finding alone does not establish asthma, and a normal test between episodes does not exclude it.
Peak expiratory flow measurements can document changes in airflow over time. In selected settings, exercise or bronchial challenge testing assesses airway responsiveness. Such testing evaluates a suspected underlying disorder rather than merely confirming the presence of wheeze.
The differential diagnosis includes inhaled foreign bodies, mucus plugging, upper-airway obstruction, inducible laryngeal obstruction, and heart failure. These conditions can produce similar symptoms but have different mechanisms. Imaging does not directly establish bronchospasm, though it may identify alternative explanations or complications.
Treatment principles
Clinical treatment addresses both airway narrowing and its cause. Inhaled beta-2 agonists, such as salbutamol—also called albuterol—relax airway smooth muscle. Inhaled antimuscarinic medicines reduce cholinergic bronchoconstriction and are used in particular clinical settings.
Corticosteroids address associated airway inflammation rather than producing immediate smooth-muscle relaxation. Supplemental oxygen and, in severe respiratory failure, mechanical ventilation may form part of hospital management. When bronchospasm occurs as part of anaphylaxis, epinephrine treats the systemic reaction; inhaled bronchodilators do not replace it.
The clinical course depends on the cause, severity, and presence of underlying airway disease. Resolution of an individual episode does not necessarily mean that the tendency to recurrent airway narrowing has disappeared.